文献速递临床试验与 GCP基础与转化研究

抗CD117抗体用于范可尼贫血的无放疗和无白消安干细胞移植:1b期试验

Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial.
PubMed 文献 · Nat Med · 2025-07-22

该1b期试验在3例范可尼贫血合并骨髓衰竭患者中评估以抗CD117抗体briquilimab替代基因毒性放化疗的预处理方案,联合兔抗胸腺细胞球蛋白、环磷酰胺、氟达拉滨、利妥昔单抗免疫抑制及TCRαβ+ T细胞去除和CD19+ B细胞去除的单倍体造血干细胞移植,未观察到治疗中出现的不良事件或急性移植物抗宿主病,达到安全性和植入主要终点。

要点

  • 3例范可尼贫血患者接受briquilimab替代放化疗预处理,均完成2年随访。
  • 未观察到治疗中出现的不良事件或急性移植物抗宿主病,毒性轻微。
  • 中性粒细胞植入中位11天(范围11-13天),供者嵌合率高达99-100%持续至移植后2年。

核心结论

  • 这些数据表明该方案在保持造血干细胞移植疗效的同时降低毒性具有广泛潜力,2期试验正在进行中(ClinicalTrials.gov标识符:NCT04784052)。

研究设计与样本

  • 1b期临床试验在范可尼贫血合并骨髓衰竭患者中评估以briquilimab为基础的预处理联合兔抗胸腺细胞球蛋白、环磷酰胺、氟达拉滨和利妥昔单抗免疫抑制及TCRαβ+ T细胞去除和CD19+ B细胞去除的单倍体造血干细胞移植的安全性和疗效。
  • 主要终点包括安全性和植入,次要终点包括药代动力学指标及血液学和免疫学恢复,所有3例患者均完成2年随访以完成1b期分析。

主要发现

  • 未观察到治疗中出现的不良事件或急性移植物抗宿主病,患者毒性轻微,表现为典型黏膜炎,无静脉闭塞性疾病。
  • 中性粒细胞植入中位11天(范围11-13天),供者嵌合率高达移植后2年99-100%,达到研究主要终点。
  • Briquilimab在每例患者移植前清除,无需调整。
  • 红细胞、血小板和淋巴细胞恢复与既往TCRαβ+ T细胞去除和CD19+ B细胞去除移植报道相当。
  • 所有患者存活且状况良好,治疗后外周血淋巴细胞中先前染色体断裂异常消失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current hematopoietic stem cell transplantation (HSCT) conditioning strategies cause widespread tissue damage and systemic toxicities, especially in patients with DNA-repair deficiencies such as Fanconi anemia (FA). We have developed an alternative conditioning approach that incorporates the anti-CD117 antibody, briquilimab, which targets host hematopoietic stem and progenitor cells in place of genotoxic irradiation- and busulfan-based chemotherapy. Here we report a phase 1b clinical trial in patients with FA and bone marrow failure, evaluating safety and efficacy of briquilimab-based conditioning in combination with rabbit anti-thymocyte globulin, cyclophosphamide, fludarabine and rituximab immunosuppression and T cell receptor (TCR)αβ+ T cell-depleted and CD19+ B cell-depleted haploidentical HSCT. Primary endpoints of the trial included safety and engraftment, and secondary endpoints included pharmacokinetic measures and hematological and immunological recovery. All three patients have each undergone 2 years of follow-up to complete the phase 1b analysis. No treatment-emergent adverse events or acute graft-versus-host disease was observed. Patients experienced minimal toxicities, with typical mucositis and no veno-occlusive disease. Median neutrophil engraftment was 11 days (range 11-13 days) with robust donor chimerism up to 2 years post-HSCT (99-100%), meeting the primary endpoints of the study. Briquilimab cleared in each patient before HSCT without the need for adjustment. Red blood cell, platelet and lymphocyte recovery was comparable to previous reports with TCRαβ+ T cell-depleted and CD19+ B cell-depleted grafts. All patients are alive and well with resolution of earlier chromosomal breakage abnormalities in peripheral blood lymphocytes post treatment. These data demonstrate the broad potential of this protocol in maintaining HSCT efficacy while reducing toxicity. The phase 2 trial is ongoing (ClinicalTrials.gov identifier: NCT04784052 ).

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Agarwal R, Bertaina A, Soco C, et al. Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial. Nat Med. 2025. PMID: 40696207. doi:10.1038/s41591-025-03817-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。